Quantification of the Triazole Antifungal Compounds Voriconazole and Posaconazole in Human Serum or Plasma Using Liquid Chromatography Electrospray Tandem Mass Spectrometry (HPLC-ESI-MS/MS)

  • Alejandro R. MolinelliEmail author
  • Charles H. RoseIV
Part of the Methods in Molecular Biology book series (MIMB, volume 1383)


Voriconazole and posaconazole are triazole antifungal compounds used in the treatment of fungal infections. Therapeutic drug monitoring of both compounds is recommended in order to guide drug dosing to achieve optimal blood concentrations. In this chapter we describe an HPLC-ESI-MS/MS method for the quantification of both compounds in human plasma or serum following a simple specimen preparation procedure. Specimen preparation consists of protein precipitation using methanol and acetonitrile followed by a cleanup step that involves filtration through a cellulose acetate membrane. The specimen is then injected into an HPLC-ESI-MS/MS equipped with a C18 column and separated over an acetonitrile gradient. Quantification of the drugs in the specimen is achieved by comparing the response of the unknown specimen to that of the calibrators in the standard curve using multiple reaction monitoring.

Key words

Antifungal Triazole Voriconazole Posaconazole Mass spectrometry Fungal infection Therapeutic drug monitoring 


  1. 1.
    Product information (2010) VFEND® (voriconazole). Available via Drugs@FDA database. Accessed 25 Feb 2015
  2. 2.
    Product information (2013) Noxafil® (posaconazole). Available via Drugs@FDA database. Accessed 25 Feb 2015
  3. 3.
    Andes D, Pascual A, Marchetti O (2009) Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53(1):24–34PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Hicks JK, Crews KR, Flynn P, Haidar CE, Daniels CC, Yang W, Panetta JC, Pei D, Scott JR, Molinelli AR, Broeckel U, Bhojwani D, Evans WE, Relling MV (2014) Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 15(8):1065–1078PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS (2012) The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 55(8):1080–1087CrossRefPubMedGoogle Scholar
  6. 6.
    Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW (2014) Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69(5):1162–1176PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Bernardo VA, Cross SJ, Crews KR, Flynn PM, Hoffman JM, Knapp KM, Pauley JL, Molinelli AR, Greene WL (2013) Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother 47(7–8):976–983PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Pennick GJ, Clark M, Sutton DA, Rinaldi MG (2003) Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 47(7):2348–2350PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Langman LJ, Boakye-Agyeman F (2007) Measurement of voriconazole in serum and plasma. Clin Biochem 40(18):1378–1385CrossRefPubMedGoogle Scholar
  10. 10.
    Gordien JB, Pigneux A, Vigouroux S, Tabrizi R, Accoceberry I, Bernadou JM, Rouault A, Saux MC, Breilh D (2009) Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal 50(5):932–938CrossRefPubMedGoogle Scholar
  11. 11.
    Pauwels S, Vermeersch P, Van Eldere J, Desmet K (2012) Fast and simple LC-MS/MS method for quantifying plasma voriconazole. Clin Chim Acta 413(7–8):740–743CrossRefPubMedGoogle Scholar
  12. 12.
    Beste KY, Burkhardt O, Kaever V (2012) Rapid HPLC-MS/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma. Clin Chim Acta 413(1–2):240–245CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesSt. Jude Children’s Research HospitalMemphisUSA

Personalised recommendations